Studies with cytotoxic agents suggest that apoptosis is not a major determinant of clonogenic death in neuroblastoma cells

European Journal of Cancer

Volumn 39, Issue 15, 2003, Pages 2234-2238

  Russell, J ^a   Ling, C C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Apoptosis; Cisplatin; Doxorubicin; Melphalan; Neuroblastoma; Perillyl alcohol; Radiation; Tamoxifen

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; MELPHALAN; PERILLYL ALCOHOL;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CLONOGENESIS; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MOLECULAR CLONING; NEUROBLASTOMA CELL; PRIORITY JOURNAL; RADIATION;

EID: 0142123300     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00488-X     Document Type: Article

References (15)

1. Lane D.P. p53, guardian of the genome. Nature. 358:1992;15-16.
2. DeVita V.T. Jr., Canellos G.P. The lymphomas. Semin. Hematol. 36:1999;84-94.
3. Yin D.X., Schimke R.T. Bcl-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res. 55:1995;4922-4928.
4. Kyprianou N., King E.D., Bradbury D., Rhee J.G. Bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int. J. Cancer. 70:1997;341-348.
5. Rudner J., Belka C., Marini P.et al. Radiation sensitivity and apoptosis in human lymphoma cells. Int. J. Radiat. Biol. 77:2001;1-11.
6. Russell J., Wheldon T.E., Stanton P. A radioresistant variant derived from a human neuroblastoma cell line is less prone to radiation-induced apoptosis. Cancer Res. 55:1995;4915-4921.
7. Klingebiel T., Bader P., Bares R.et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur. J. Cancer. 34:1998;1398-1402.
8. Kushner B.H., Heller G., Kramer K., Cheung N.K. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma. Cancer. 89:2000;2122-2130.
9. Ripple G.H., Gould M.N., Stewart J.A.et al. Phase I clinical trial of perillyl alcohol administered daily. Clin. Cancer Res. 4:1998;1159-1164.
10. Ariazi E.A., Satomi Y., Ellis M.J.et al. Activation of the transforming growth factor beta signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res. 59:1999;1917-1928.
11. Stayrook K.R., McKinzie J.H., Barbhaiya L.H., Crowell P.L. Effects of the antitumor agent perillyl alcohol on H-Ras vs. K-Ras farnesylation and signal transduction in pancreatic cells. Anticancer Res. 18:1998;823-828.
12. Wei X., Si M.S., Imagawa D.K.et al. Perillyl alcohol inhibits TCR-mediated [Ca(2+)](i) signaling, alters cell shape and motility, and induces apoptosis in T lymphocytes. Cell Immunol. 201:2000;6-13.
13. Howell N., Belli T.A., Zaczkiewicz L.T., Belli J.A. High-level, unstable adriamycin resistance in a Chinese hamster mutant cell line with double minute chromosomes. Cancer Res. 44:1984;4023-4029.
14. Ireland C.M., Pittman S.M., Jones S.L., Harnett P.R. Establishment of an in vitro model for cisplatin resistance in human neuroblastoma cell lines. Anticancer Res. 14:1994;2397-2403.
15. Moscow J.A., Swanson C.A., Cowan K.H. Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br. J. Cancer. 68:1993;732-737.